A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony diagnoza raka płuca (zaawansowany, z przerzutami)
- •Widoczne zmiany nowotworu możliwe do zmierzenia na badaniach obrazowych
- •Dostarczona próbka tkanki nowotworu (pobrana przy diagnozie lub później)
- •Nieprzyjemne skutki uboczne poprzedniego leczenia muszą się cofnąć
- •Zakażeni HIV muszą mieć chorobę kontrolowaną lekami
- •Stan ogólny pacjenta oceniony w ostatnich 7 dniach
- •Oczekiwana przeżywalność co najmniej 3 miesiące
- •Prawidłowe funkcjonowanie narządów wewnętrznych
✗ Disqualifies
- •Zakażenie HIV z historią mięsaka Kaposiego lub choroby Castelmana
- •Poprzednie leczenie szczepionką przeciwnowotworową
- •Poprzednie systemowe leczenie raka
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (54)
Moffitt Cancer Center ( Site 0021)
Tampa, United States
Washington University School of Medicine ( Site 0024)
St Louis, United States
Valley Health Systems - Ridgewood Campus ( Site 0010)
Paramus, United States
New York Oncology Hematology (NYOH) - Albany Medical Center ( Site 9001)
Albany, United States
Cleveland Clinic - Ohio ( Site 0016)
Cleveland, United States
Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025)
Corvallis, United States
Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)
Nashville, United States
Texas Oncology - Central/South Texas ( Site 8002)
Austin, United States
Virginia Cancer Specialists ( Site 0003)
Fairfax, United States
Swedish Medical Center-Swedish Cancer Institute ( Site 0023)
Seattle, United States
Hospital Italiano de Buenos Aires ( Site 0200)
Ciudad Autonoma de Buenos Aires., Argentina
Instituto Alexander Fleming ( Site 0201)
Ciudad Autonoma de Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0205)
Mar del Plata, Argentina
Clinica Adventista Belgrano ( Site 0206)
Caba., Argentina
Fundacion Estudios Clinicos ( Site 0207)
Rosario, Argentina
Sanatorio Parque ( Site 0203)
Rosario, Argentina
Westmead Hospital ( Site 0400)
Westmead, Australia
Princess Alexandra Hospital ( Site 0403)
Woolloongabba, Australia
One Clinical Research ( Site 0402)
Nedlands, Australia
Centro de Estudios Clínicos SAGA ( Site 0307)
Santiago, Chile
FALP ( Site 0300)
Santiago, Chile
Bradfordhill ( Site 0301)
Santiago, Chile
Bradford Hill Norte ( Site 0308)
Antofagasta, Chile
Centre Georges François Leclerc ( Site 0805)
Dijon, France
Institut de Cancérologie de l'Ouest ( Site 0801)
Angers, France
CHU GABRIEL MONTPIED ( Site 0802)
Clermont-Ferrand, France
Ospedale Santa Maria delle Croci-Dipartimento Oncoematologico ( Site 1004)
Ravenna, Italy
Ospedale San Raffaele-Oncologia Medica ( Site 1002)
Milan, Italy
Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 1000)
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1001)
Roma, Italy
Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 1101)
Poznan, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 1100)
Warsaw, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1102)
Przemyśl, Poland
National Cancer Center ( Site 0504)
Goyang-si, South Korea
Seoul National University Bundang Hospital ( Site 0500)
Seongnam-si, South Korea
Chungbuk National University Hospital-Internal medicine ( Site 0501)
Cheongju-si, South Korea
Asan Medical Center ( Site 0503)
Seoul, South Korea
Samsung Medical Center ( Site 0502)
Seoul, South Korea
ICO L Hospitalet ( Site 1311)
Hospitalet, Spain
Hospital Jerez de la Frontera-UGC Oncología ( Site 1315)
Jerez de la Frontera, Spain
Hospital Universitari Vall d''Hebron ( Site 1310)
Barcelona, Spain
Hospital Ramon y Cajal ( Site 1314)
Madrid, Spain
Hospital Clinico San Carlos... ( Site 1313)
Madrid, Spain
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1312)
Seville, Spain
China Medical University Hospital ( Site 0606)
Taichung, Taiwan
National Cheng Kung University Hospital ( Site 0601)
Tainan, Taiwan
Mackay Memorial Hospital ( Site 0604)
Taipei, Taiwan
National Taiwan University Cancer Center (NTUCC) ( Site 0600)
Taipei, Taiwan
Taipei Veterans General Hospital ( Site 0602)
Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 0605)
Taoyuan, Taiwan
Hacettepe Universitesi Tıp Fakultesi ( Site 1400)
Ankara, Turkey (Türkiye)
Memorial Ankara Hastanesi ( Site 1401)
Ankara, Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi ( Site 1402)
Ankara, Turkey (Türkiye)
Koç Üniversitesi Hastanesi ( Site 1403)
Istanbul, Turkey (Türkiye)
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.